The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Amedisys (AMED) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Amedisys is a member of our Medical group, which includes 867 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AMED is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AMED's full-year earnings has moved 0.69% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, AMED has returned 12.27% so far this year. Meanwhile, stocks in the Medical group have gained about 1.97% on average. As we can see, Amedisys is performing better than its sector in the calendar year.
To break things down more, AMED belongs to the Medical - Outpatient and Home Healthcare industry, a group that includes 17 individual companies and currently sits at #36 in the Zacks Industry Rank. Stocks in this group have gained about 10.61% so far this year, so AMED is performing better this group in terms of year-to-date returns.
AMED will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amedisys, Inc. (AMED) : Free Stock Analysis Report
To read this article on Zacks.com click here.